The EBMT Handbook

<div>Part I.&nbsp;</div><div>Chapter. 1 HSCT: Historical perspective</div><div>Storb, R</div><div>Chapter. 2 The EBMT: History, present & future</div><div>Apperley, J;&nbsp; Gratwohl, A; Mohty, M</div><div>Chapter. 3 The donor registries (organization, regulation, international search...) </div><div>Madrigal, A; Evseeva, Irina</div><div>Chapter. 4 The HSCT Unit (minimal requirements, data manager trasplant coordinator) </div><div>Aljurf, M; Niederwieser, Dietger; Rasheed, Walid</div><div>Chapter. 5 JACIE accreditation of HSCT programs </div><div>Saccardi, R</div><div>Chapter. 6</div><div>Statistics in HSCT and Cellular Therapies </div><div>Labopin, M; Iacobelli, S; de Wreede, Liesbeth; Szydlo, Richard</div><div><br></div><div>Part II.&nbsp;</div><div>Chapter. 7 Biological properties of HSC: scientific basis for HSCT </div><div>Chabannon, C ; Aiuti, M</div><div>Chapter. 8 Biological properties of cells other than HSC (adaptative, abT, Treg, DC. Innete gdT, IELs MSC, NK) </div><div>Toubert, A; Koehl, U; Bondanza, A</div><div>Chapter. 9 Histocompatibility (main concepts on HLA) </div><div>K. Fleischhauer; Spierings</div><div>Chapter. 10 Clinical & biological concepts for mastering Immune reconstitution after HSCT</div><div>Boelens, J; Kuball, J</div><div><br></div>Part III.&nbsp;<div>Chapter. 11 Evaluation and counselling of candidates </div><div>Rambaldi, A</div><div>Chapter. 12 Donor selection&nbsp; for adults and pediatrics </div><div>Ayuk, F; Balduzzi, A</div><div>Chapter. 13 Conditioning (MAC, RIC, NMA; including TBI) </div>Nagler, A<div>Chapter. 14 Bone marrow harvest </div><div>Gorin, Claude</div><div>Chapter. 15 Mobilization and collection of HSC </div><div>Hübel, K</div><div>Chapter. 16 Collection of HSC in children</div><div>Peters, C; Witt, Volker</div>Chapter. 17 Processing, cryopreserving, and controlling the quality of HSC <div>Wuchter, Patrick</div><div>Chapter. 18 Procurement and management of cord blood</div><div>Rocha, V; Querol, S</div><div>Chapter. 19 Graft manipulation </div><div>Handgretinger, R</div><div>Chapter. 20 Documentation of engraftment and chimerism after HSCT </div><div>Bader, P</div><div>Chapter. 21 Short and long term controls after HSCT </div><div>Shimoni, A</div><div><br></div><div>Part IV.&nbsp;</div><div>Chapter. 22 Vascular access </div>Cesaro, S<div>Chapter. 23 Transfusion support</div><div>Schrezenmeier, H</div><div>Chapter. 24 Fluid and electrolyte management</div><div>Masszi, T; Baumgartner, Annic</div><div>Chapter. 25 GVHD prophylaxis (immunosuppression) </div><div>Socié, G</div>Chapter. 26 Management ATG (SIRS) <div>F. Bonifazi</div><div>Chapter. 27 Infections control and isolation procedures </div><div>Mikulska, M&nbsp;&nbsp;</div><div>Chapter. 28 Pain management </div><div>Ahmedzai, SH</div><div>Chapter. 29 Specific aspects of management in children</div><div>Castagnola, Elio; Riccardi, F</div><div>Chapter. 30 Vaccinations </div><div>de la Cámara, Rafa</div><div>Chapter. 31 Psychological support </div><div>Moreno, E ; Schulz-Kindermann, F ; Polomeni, Alice</div><div>Chapter. 32 Relevant pharmacological interaction </div><div>Bauters, T</div><div>Chapter. 33 Role of nursing in HSCT </div><div>Babic, A; Murray, J</div><div>Chapter. 34 Ethical issues in HSCT </div><div>Dalle, JH; El-Ghariani, K</div><div><br></div><div>Part V.&nbsp;</div><div>Chapter. 35 Quality assessment of life after HSCT for pediatric and adults </div><div>Barata, Anna; Jim, Heather</div><div>Chapter. 36 Neutropenic fever </div><div>Mikulska, M&nbsp;&nbsp;</div><div>Chapter. 37 Bacterial infections </div><div>Averbuch, D</div>Chapter. 38 Invasive fungal infections <div>Maertens, J</div><div>Chapter. 39 Viral infections (CMC, EVB, VZV, HSV, HHV6, Resp. V, HCV, HBV…) & anti-viral cell therapy</div><div>Ljungman, P; Styczynski, J; Einsele, Hermann</div><div>Chapter. 40 Other infections in HSCT (Tuberc, Toxo, PCJ, Noc, List.) </div><div>Martino, R</div>Chapter. 41 Bleeding and thrombotic complications<div>Savani, B</div><div>Chapter. 42 Graft failure</div><div>Valcárcel , D; Sureda, A</div><div>Chapter. 43 Early complications of endothelial origin </div><div>Carreras, E</div><div>Chapter. 44 Acute GvHD </div><div>Greinix, H; Holler, E; Zeiser, R</div><div>Chapter. 45 Chronic GvHD </div><div>Wolff, D; Lawitschka, A</div><div>Chapter. 46 Post-transplant lymphoproliferative syndromes</div><div>Styczynski, J ; Giebel, S</div><div>Chapter. 47 Iron overload</div><div>Angelucci, E</div><div>Chapter. 48 Secondary neoplasia (other than PTLPS) </div><div>Tichelli, A</div><div><br></div><div>Part VI.&nbsp;</div><div>Chapter. 49 Specific organ complications: Ocular / oral / pulmonary / hepatic </div><div>Ruutu, T; Hashmi, S</div><div>Chapter. 50 Gastrointestinal complications</div><div>Basak, G</div><div>Chapter. 51 Hemorrhagic cystitis and renal dysfunction</div><div>Cesaro, S</div><div>Chapter. 52 Pulmonary complications </div><div>Carreras, E</div><div>Chapter. 53 Neurological complications </div><div>Duléry, R</div><div>Chapter. 54 Specific organ complications: Skin, hair, musculoskeletal </div><div>Ayuk, F; Savani, B</div><div>Chapter. 55 Cardiovascular diseases and metabolic syndrome </div><div>Snowden, J; Greenfield, D</div><div>Chapter.&nbsp; 56 Endocrine, fertility and sexual health</div><div>Salooja, N; Shoham,&nbsp; Z; Balduzzi, A</div><div><br></div><div>Part VII.&nbsp;</div><div>Chapter. 57 Monitoring MRD in ALL </div><div>Bader, P; Ossenkoppele, G</div><div>Chapter. 58 Preventing/treating relapse with drugs</div><div>Kröger, N; Mohty, M</div><div>Chapter. 59 Preventing relapse by mean cells (DLI, aBT, subsets, tumour specific T cells)</div><div>&nbsp;Kuball, J; Falkenburg, JH Fred; Kolb, HJ; Locatelli, F</div><div>Chapter. 60 Cellular therapy (CAR T, TCR T, suicide genes) with management and side effects</div><div>Bonini, C; Hudecek, Michael; Fehse, Boris; Bondanza, A</div><div>Chapter. 61 Mechanisms of Immune resistance and overcoming immune resistance (checkpoint…)</div><div>Dazzi, F; Vago, L</div><div>Chapter. 62 Regulatory Aspects of ATMP versus minimally manipulated immune cellsMc Grath, E; Chabannon, C&nbsp;</div><div><br></div><div>Part VIII.&nbsp;</div><div>Chapter. 63 At-home HSCT </div><div>Fernández-Avilés, F</div><div>Chapter. 64 Cord blood HSCT (adults & children) </div><div>Veys, P; Rocha, V; Sanz, J</div><div>Chapter. 65 Haploidentical HSCT (TCD and TC-repleted)</div><div>Ciceri, F ; Bacigalupo, A</div><div>Chapter. 66 Photopheresis in adults and pediatrics </div><div>Greinix, H; Gennery, A</div><div>Chapter. 67 Pediatric aspects of haploidentical HSCT </div><div>Gennery, A; Bertaina, A; Slatter, M; Lankester, A; Albert, M</div><div>Chapter. 68 Overweight and obese patients </div><div>Langebrake, C&nbsp;</div><div>Chapter. 69 HSCT in Elderly patiens </div><div>Duarte, R</div><div><br></div><div>Part IX.&nbsp;</div><div>Chapter. 70 EBMT indication for allo and auto HSCT </div><div>BOARD</div><div>Chapter. 71 AML in adults (incl APL) </div><div>Nagler, A; Cornelissen, J; Craddock, C; Sanz, MA</div><div>Chapter. 72 AML in children </div><div>Gibson, B ; Sauer, M</div><div>Chapter.&nbsp; 73 ALL in adults </div><div>Marks, D ; Stelljes, M</div><div>Chapter. 74 ALL in children and adolescents </div><div>Peters, C; Locatelli, F; Bader, P</div><div>Chapter. 75 Myelodysplastic syndromes </div><div>de Witte, T; Robin, M</div><div>Chapter. 76 Refractory Anemia and JMML in children </div>Niemeyer, CM<div>Chapter. 77 Myelodysplastic/myeloproliferative syndromes </div><div>Onida, F; Chalandon, Y&nbsp;</div><div>Chapter. 78 Myeloproliferative neoplasms (CML, PM, other MPN) </div><div>Olavarria E; Kröger, N</div><div>Chapter. 79 Severe aplastic anemia and PNH</div><div>Dufour C; Peffault de la Tour,&nbsp; R; Risitano, Antonio Maria</div><div>Chapter. 80 Fanconi anemia and other hereditary BMF syndromes</div><div>Fioredda, F; Strahm, B; Diaz de Heredia, Cristina; Dalle, JH; Bierings, Marc</div><div>Chapter. 81 Hemoglobinopathies (SCA)</div><div>Gluckman, E; Abboud, Miguel</div><div>Chapter. 82 Multiple myeloma </div><div>Mohty, M; Blade, Joan; Bruno, B</div><div>Chapter.&nbsp; 83 Systemic light chain amyloidosis </div><div>Schönland, S; Minnema, M</div><div>Chapter. 84 POEMS syndrome and disease produced by other monoclonal Igs </div><div>Cook, G; Rovira, M</div><div>Chapter. 85 Low grade NHL (follicular, MALT, MW) </div><div>Robinson, S; Kyriacou, C</div><div>Chapter. 86 Chronic lymphoid leukemia </div><div>Dreger, P; Schetelig, Johannes</div><div>Chapter. 87 Diffuse large B cell NHL </div><div>Bazarbachi, A; Schmitz, N</div><div>Chapter. 88 Mantle cell lymphoma </div><div>Dietrich, S; Hermine, O</div><div>Chapter. 89 Other T- and B-aggressive lymphomas (Burkitt, LL, PTCL) & Lymphomas associated to HIVHübel, K; Montoto, S</div><div>Chapter. 90 Hodgkin lymphoma </div><div>Sureda, A; Martinez, Carmen</div><div>Chapter. 91 Primary immunodeficiency diseases</div><div>Lankester, A; Gennery, A; Albert, M</div><div>Chapter. 92 Inborn error of metabolism and osteopetrosis </div><div>Schulz, A; Wynn, R</div><div>Chapter.93 Autoimmune disease </div><div>Snowden, J; Rovira, M; Alexander, T ; Sharrack, B ; Farge, D</div><div>Chapter.94 Solid tumors (adults and children)</div><div>Lanza, F; Ladenstein, R</div><div><br></div><div>Appendix</div><div>EBMT Registry </div><div>Ruiz, C; Hewer</div>